Monday, June 22, 2026

CMS LCD History: How "CAC" Meetings Evolved (2005, 2015, 2019)

 Medicare's contractor advisory committees have evolved greatly from 2005, to 2015, to the present (2019 forward).   I've put the Medicare LCD Manual from each period into one cloud zip file (here).

I asked Chat GPT to evaluate and compare CAC meetings under each era.

###

Core thesis

The CMS CAC evolved from a standing, state-based professional advisory committee embedded in the draft-LCD comment cycle into a more flexible, evidence-review body that MACs may convene around a topic, often before a proposed LCD is released. In 2004 and still largely in 2015, the CAC was part of the old carrier-era culture: one committee per state, regular meetings, local specialty society representation, minutes, agendas, and draft LCDs distributed to CAC members at the same time the 45-day comment period began. By 2019, after 21st Century Cures and CMS’s broader LCD-process revisions, the CAC had become more formalized as a transparency and evidence-review mechanism: open to public observation, recorded, potentially jurisdictional or multi-jurisdictional, and explicitly focused on the quality of evidence rather than simply “local physician input.”

CMS itself described the 2018–2019 Chapter 13 revision as a response to the 21st Century Cures Act, intended to improve transparency in the LCD process. (Centers for Medicare & Medicaid Services)

2004: the CAC as a standing state advisory committee

The 2004 model was recognizably a local medical advisory committee model. The manual said carriers “shall establish one CAC per State,” and if one carrier served multiple states, “each State shall have a full committee and the opportunity to discuss draft LCDs and issues presented in their State.” A single jurisdiction-wide CAC was possible, but only with regional-office permission and agreement from CAC members in the jurisdiction.

The purpose was broad and relational. The CAC existed to give physicians in the state a formal way to be informed of and participate in LCD development, to improve administrative policies within carrier discretion, and to serve as an information-exchange forum between carriers and physicians. The manual also made clear what the CAC was not: it was not peer review, not a forum for individual cases, and not about private-insurance issues. The final LCD decision rested with the contractor medical director, but the CAC was expected to review all draft LCDs.

Operationally, the 2004 CAC was a roster-based committee. Each specialty had one member and an alternate. Members were expected to disseminate proposed LCDs to colleagues and specialty societies, gather comments, and bring feedback to the contractor. This made the CAC partly a professional-society relay network: the carrier did not merely ask six experts for views; it used CAC members as conduits to state and specialty communities.

The meeting cadence was also institutionalized. The manual required at least three meetings per year, with no more than four months between meetings, except for a one-time transition from four to three annual meetings. That is very close to the “quarterly standing committee” world you describe. The draft-LCD process was tied to this cadence: the 45-calendar-day comment period began when the proposed LCD was distributed to committee members, and the co-chairs presented all proposed LCDs to the CAC for discussion.

This is the key 2004 norm: CAC review and public draft release were not sharply separated events. The CAC often saw the proposed LCD as part of the formal draft process, and its advisory role was interwoven with the public-comment machinery.

2015: continuity with the old model, not yet the Cures-era model

The 2015 excerpt is striking because it shows how much of the old 2004 model survived. The section still required one CAC per state, still contemplated a waiver for a single jurisdiction-wide CAC, and still emphasized a “formal mechanism for physicians in the State” to participate in LCD development.

The 2015 version retained the same basic membership structure: physicians, a beneficiary representative, and representatives of medical organizations. It retained the same member role: disseminate proposed LCDs, disseminate Medicare information back to specialty societies, and discuss inconsistent or conflicting medical-review policies.

The 2015 manual also retained the old co-chair model: the CAC was co-chaired by the contractor medical director and a physician selected by the committee. The co-chairs ran meetings, set agendas, provided background materials at least 14 days in advance, and encouraged committee members to consult with colleagues before the meeting.

Most importantly, 2015 still described the CAC as “the primary forum for discussion of proposed LCDs developed by the CMD,” and still stated that the 45-day comment process began when the draft LCD was distributed to committee members.

So 2015 was not yet a modern “public evidence panel” model. It was still essentially the legacy carrier/CMD model, despite the fact that the Medicare contractor world had moved from older “carriers” toward MACs. The CAC remained local, standing, semi-representational, and connected to the release of draft LCDs.

2019: the Cures-era CAC becomes an evidence-review and transparency device

The 2019 language is much shorter but conceptually very different. It no longer reads primarily like a manual for managing standing state medical committees. Instead, it reads like a rule for ensuring that, when a CAC is used, it supports transparent, evidence-based LCD development.

The 2019 section still says MACs shall establish one CAC per state, but it adds that they may establish one CAC per jurisdiction or a multi-jurisdictional CAC with representation from each state. That is a major structural change. It reflects the MAC era: large jurisdictions, consolidated contractor organizations, and increasingly national or multi-jurisdictional LCD topics.

The purpose also changes in tone. In 2004/2015, the purpose was for physicians to be informed of and participate in LCD development and to improve local administrative policies. In 2019, the purpose is to inform healthcare professionals of “the evidence used in developing the LCD,” promote communication, and have CAC members review the quality of the evidence used in LCD development.

That shift is important. The CAC is no longer simply a physician-community sounding board. It is an evidentiary advisory body. The manual says the advice is most useful when it results from “full scientific inquiry,” “thoughtful discussion,” “careful framing of recommendations,” and clear identification of the basis for those recommendations.

Membership language also broadens. The older text repeatedly foregrounded physicians. The 2019 text uses “healthcare professionals,” beneficiary representatives, and representatives of medical organizations. It says CAC members are valued for background, education, experience, and expertise in scientific, clinical, and related fields.

This was not merely semantic. It permitted a CAC on a molecular diagnostic, AI pathology, neurology biomarker, wound-care device, or interventional pain procedure to include the people who actually understand the evidence base, even if they are not simply the traditional local state-specialty-society designee. That helps explain the modern pattern you describe: a small group of topic-specific experts, often nationally prominent, assembled to answer structured evidentiary questions.

Transparency: the public, the recording, and the LCD record

The 2019 CAC became part of the public LCD record in a much stronger way. The manual says MACs shall record CAC meetings by video, audio, or both, maintain the recording on the contractor website as part of the LCD record, and make all CAC meetings open to the public to attend and observe, except for portions not discussing evidence for a proposed LCD, such as fraud-and-abuse or provider-practice-trend discussions.

That is a very different public-law posture from the 2004/2015 minutes model. Earlier, contractors kept minutes, distributed them to members, sent them to CMS regional staff, and were encouraged—but not required—to prepare a web version. In 2019, the CAC is recorded and posted as part of the LCD record.

This is the bridge to the 2026-style meeting. Once the CAC is public, recorded, and evidence-focused, it naturally becomes more like a structured public workshop: selected experts, defined questions, time-limited discussion, transcript or recording, and later use of the discussion in the LCD record.

The sequencing changed: from “draft LCD review” to “pre-LCD evidence workshop”

The largest practical change is sequencing.

In 2004/2015, the CAC was tied to the draft LCD: proposed LCDs were presented to the CAC, and the 45-day comment clock began when the draft was distributed to CAC members. The CAC’s function was therefore partly contemporaneous with public release.

In the modern process, the CAC may occur before a proposed LCD exists. Current contractor descriptions commonly list consultation and CAC activity, “if necessary,” before publication of a proposed LCD, followed by the open meeting and the 45-day written-comment period. For example, Noridian’s current LCD-development description lists consultation with requestors or subject-matter experts, then a CAC meeting “if necessary,” then publication of a proposed LCD, then an open meeting and written comment period. (Medicare)

That is the operational pivot. The CAC is no longer simply the body to which a draft LCD is shown. It can be used earlier to help the MAC understand the evidence landscape before the MAC writes the proposed LCD.

Why the modern CAC feels like a CMS-style workshop

The 2026 pattern you describe—six or so selected specialists, national credentials, a two-hour agenda, 10–12 structured questions, and a transcript—is a logical outcome of several forces.

First, LCD topics became more technically complex. A state roster of 20 standing physicians could discuss common local utilization issues, but it may not be the best format for plasma Alzheimer biomarkers, amyloid PET, AI pathology, molecular oncology, or novel neuromodulation devices. The MAC needs experts who know the evidence.

Second, MAC jurisdictions became larger and more standardized. A single MAC often covers multiple states, and some LCDs are effectively national in impact even though legally local. A state-by-state CAC structure fits poorly when the same LCD language is used across broad jurisdictions or across the MolDx system.

Third, 21st Century Cures forced CMS to emphasize transparency, evidence summaries, public process, and the rationale for LCD decisions. CMS’s 2018 fact sheet described the Chapter 13 changes as designed to improve LCD transparency. (Centers for Medicare & Medicaid Services) The American Hospital Association summarized the reforms as expanding CAC participation, opening CAC meetings to the public, and requiring a standardized summary of the clinical evidence supporting an LCD decision. (American Hospital Association)

Fourth, the modern CAC is no longer mainly a local political feedback loop. It is closer to an evidentiary hearing. The experts are asked about study design, endpoints, generalizability, patient selection, clinical utility, guideline concordance, and harms. The MAC then has a record it can cite or consider when drafting the LCD.

What was lost in the evolution

Something was gained, but something was also lost.

The 2004/2015 CAC had a local-professional legitimacy function. It gave state medical societies, specialty societies, and local physicians a standing channel into Medicare contractor policy. CAC members could disseminate draft LCDs to colleagues and bring local objections back to the contractor. That model was cumbersome, but it embedded LCD development in a continuing relationship between the CMD and the local medical community.

The 2019/2026 model is more transparent and more scientifically focused, but less communitarian. A hand-picked panel of national experts can provide better evidence analysis, but it may not represent the lived administrative experience of community physicians, laboratories, hospitals, or beneficiaries in a particular state. It is also less like a deliberative standing committee and more like a one-time expert consultation.

What was gained

The gains are real. Modern CACs can be more technically competent, more transparent, and more useful for controversial technologies. The public can observe. The recording or transcript becomes part of the record. The questions can be carefully framed. The MAC can ask whether evidence is sufficient for Medicare coverage, what patient population is appropriate, what outcomes matter, and what evidentiary gaps remain.

This is especially valuable for diagnostics. A traditional CAC could easily devolve into “do local physicians want this test?” A modern CAC can ask: What clinical utility evidence exists? Is the test analytically valid? Is the intended-use population clear? Does the result change management? Are guidelines concordant? Are outcomes direct or inferred? Is the evidence sufficient for Medicare’s reasonable-and-necessary standard?

Bottom line

From 2004 to 2015, CACs were still essentially standing state-based advisory committees linked to draft-LCD release and local physician communication. By 2019, CMS had recast CACs as transparent, evidence-focused, potentially jurisdictional or multi-jurisdictional advisory bodies, open to public observation and recorded as part of the LCD record. By 2026, the practical form often looks like a topic-specific expert workshop: fewer members, more national experts, structured questions, a public transcript, and a role upstream of the proposed LCD.

The legal label remained “CAC,” but the institutional object changed substantially. It moved from a standing local advisory committee that reviewed draft LCDs to a public-facing evidentiary panel that helps create the record from which a future LCD may be written.


 

 ###

Claude Opus 4.8

###


From Carrier to Contractor: How Medicare Rebuilt the CAC Between 2004 and 2019

A reading of three Program Integrity Manual layers — and why today's Contractor Advisory Committee looks nothing like the standing state roster of 2005.

If you have ever sat on a Carrier Advisory Committee, the modern CAC can be disorienting. The thing many of us remember from 2005 was a standing roster of specialists — one seat per specialty society, often fifteen or twenty members, meeting quarterly in a hotel conference room, receiving each draft Local Coverage Determination as it went out the door to public comment. The thing we attend in 2026 is something else entirely: a half-dozen experts, frequently national rather than in-state, convened for a single afternoon to work through ten or twelve structured questions about the evidence on a topic that does not yet have a draft LCD attached to it — the whole session recorded and posted as a transcript.

That transformation is fully documented in three sedimentary layers of one manual chapter. Reading them in sequence shows that the change was not a gradual drift. It was a single, discontinuous response to a statute, bolted onto more than a decade of deferred housekeeping.

Read the revision stamps first

The three documents are not freestanding policies. They are the same Program Integrity Manual section at three points in time, and the revision stamps tell most of the story before you read a word of substance.

The 2004 text carries Rev. 63 (01-23-04) and sits in the old PIM numbering as §8.1. The 2015 text is the same manual, renumbered to §13.8.1, but its bones are still Rev. 71 (04-09-04), with the structure-and-process subsection bumped only to Rev. 473 (06-21-13). The 2019 text is a different creature altogether: Rev. 863, issued 02-12-19, effective 10-03-18, implementation January 8, 2019, relocated to §13.2.4.3.

That January 8, 2019 date is the tell. It is the go-live date of CMS's wholesale rewrite of the LCD process, issued under Change Request 10901 to carry out Section 4009 of the 21st Century Cures Act (P.L. 114-255, signed December 13, 2016), codified at Social Security Act §1862(l)(5)(D). So you are really comparing two eras, not three: a carrier-era artifact that barely moved between 2004 and 2015, and a Cures-driven reconstruction in 2019.

Sidebar — The CAC across three manual layers

Feature 2004 (Rev. 63) 2015 (Rev. 71 / 473) 2019 (Rev. 863)
Name Carrier Advisory Committee Carrier Advisory Committee (text still says "Carriers") Contractor Advisory Committee; actor is the MAC
Geography One CAC per state, rigidly One CAC per state, rigidly Per state, per jurisdiction, or multi-jurisdictional / multi-MAC
Membership theory Specialty representation; one seat + alternate per specialty Same Evidence expertise; "more voices" (nurses, epidemiologists, etc.)
Core function Dissemination & liaison; carry drafts to societies Same Review the quality of the evidence
Link to comment clock 45-day clock starts on distribution to the committee Same Severed; comment period is a separate statutory step
Timing vs. draft CAC reviews the draft LCD as released Same May meet before a proposed LCD exists, on the topic's evidence
Cadence ≥ 3 meetings/year, ≤ 4 months apart Same No minimum; MAC sets frequency by LCD volume
Leadership CMD + elected physician co-chair; 2–3 yr tenure Same Co-chair / tenure language dropped; MAC approves members
Transparency Minutes to members & RO; web posting optional Same (+ PSC/GTL overlay) Recorded (audio/video), public, posted as LCD record
Compensation None; voluntary service None None (the one provision carried forward verbatim)

2004–2015: the standing state roster as a representation machine

In the first era the committee is the Carrier Advisory Committee, and almost every structural choice flows from that one word. One CAC per state; where a carrier spanned several states, each state got "a full committee and the opportunity to discuss draft LCDs." The committee was built around specialty representation: one member plus a designated alternate per specialty, with additional specialists pulled in when their expertise was implicated. In practice that produces exactly the body many of us remember — a standing roster running to fifteen or twenty seats, because the design goal was to have the relevant society's voice already in the room for whatever LCD surfaced.

The functional theory was dissemination and liaison, not adjudication of evidence. The "Role of CAC Members" section is explicit: members existed to carry proposed LCDs back out to their state and specialty societies to solicit comment, to carry Medicare program information back in, and to flag inconsistent or conflicting medical-review policy. They were conduits. The contractor medical director co-chaired with one physician elected by the committee, and the co-chairs set the agenda and pushed background material out at least fourteen days ahead.

Two features matter most for understanding what later broke. First, the CAC was wired directly into the comment clock: the 45-day comment period "starts when the proposed LCD is distributed to the committee members," and the co-chairs "present all proposed LCDs to the CAC for discussion." The CAC meeting was the public-facing event for a draft LCD — which is precisely the co-distribution-to-CAC-and-public simultaneity of the 2005 model. Second, the cadence was fixed and frequent: a minimum of three meetings a year, no more than four months apart. That is a standing quarterly body by design, because a standing body is what you need when the committee is the routing point for every draft in the jurisdiction.

What is striking is how little changed by 2015. The Medicare Modernization Act had already replaced carriers with A/B MACs years earlier, yet the 2015 text still says "Carriers shall establish," still says one CAC per state, still prescribes three meetings a year, still triggers the comment clock on distribution to the committee, still names an elected physician co-chair, still suggests two- to three-year tenures. The only real accretion is a maintenance overlay reflecting the program-integrity contractor apparatus — the parenthetical "(for PSCs, the GTL, Co-GTL, and SME)" threaded through the directory, waiver, and recordkeeping provisions — plus the 2013 (Rev. 473) refresh of the structure section. Between 2004 and 2015, CMS updated the plumbing references and left the committee's constitutional theory entirely intact. The 2015 document is a carrier-era document wearing a MAC-era nametag.

2019: the Cures rupture

The 2019 rewrite changes the committee's purpose, not merely its logistics, and nearly everything else follows from that.

Carrier becomes Contractor. The committee is renamed, the actor throughout is "MACs," and the carrier vocabulary is finally retired a decade and a half late.

The geographic unit is loosened. Where the old rule was rigidly one-CAC-per-state, 2019 permits one CAC per state, one per jurisdiction, or a multi-jurisdictional CAC with representation from each state — and CMS's companion LCD Process Q&A confirms that multi-MAC CACs are also on the table. This is the textual hinge that permits the modern reality. Once you may convene a single panel for an eleven-state jurisdiction, the chair of pathology at one academic center and the chair at another become natural picks, because you are no longer staffing for in-state representation. You are staffing for the best available evidence reviewers.

Representation becomes evidence review. This is the conceptual core. The old purpose — a formal mechanism for physicians in the state to be informed of and participate in LCD development, plus a liaison forum — is replaced by a purpose centered on the evidence: members "review the quality of the evidence used in the development of an LCD." CMS said the quiet part plainly in the Q&A: because Cures now requires LCDs to include a summary of the evidence considered and a rationale, the role of CAC members should evolve to reviewing the quality of that evidence instead of only representing a constituency. The 2019 language even imports the deliberative register of the national MEDCAC — advice is "most useful when it results from a process of full scientific inquiry and thoughtful discussion with careful framing of recommendations," and the panel exists to ensure an "unbiased and contemporary consideration of 'state of the art' technology and science." That is consciously MEDCAC-style framing dropped onto a local body.

The comment-clock coupling is severed. Note what disappears: the entire mechanism by which distributing a draft LCD to the committee started the 45-day clock, and the instruction that co-chairs present "all proposed LCDs" to the CAC. This is the most consequential deletion. Cures created, by statute, a separate and mandatory public process — the MAC must post the determination in its entirety, identify where and when it was first made public, and supply a rationale, at least forty-five days before the effective date. Once the open public-comment period and the proposed-LCD posting are independent statutory steps, the CAC no longer needs to be the comment vehicle. It is freed to move upstream: it now convenes around a contemplated topic and its evidence base. The Q&A makes the new optionality explicit — a MAC may host the CAC before posting a proposed LCD, to inform the upfront analysis, or after. That is exactly the shift from the 2005 picture (draft presented to the roster, co-distributed to the public, clock running) to the 2026 picture (a future topic, structured evidence questions, no draft on the table yet).

Transparency is mandated, and it reshapes the format. The 2019 rule requires the MAC to record every CAC meeting — video, audio, or both — and to maintain that recording on the contractor website as part of the LCD record. All CAC meetings are open to the public to attend and observe; only the non-evidence portions (provider practice-trend reporting, fraud-and-abuse discussion) may be closed. The old regime asked only for minutes distributed to members and forwarded to the regional office within ten days, with web posting optional and FOIA-redacted. The published transcript of a modern CAC is the direct artifact of this recording-and-posting mandate, and the structured, ten-to-twelve-question, roughly two-hour format is the natural operational form of "review the quality of the evidence" plus "careful framing of recommendations." It is a local echo of the MEDCAC voting-question script, engineered to produce a clean, citable evidentiary record rather than a roundtable of society liaisons.

The standing body dissolves into an ad hoc panel. Several deletions point the same way. The fixed cadence is gone; the Q&A confirms MACs now set frequency "based on the appropriateness and volume of LCDs requiring CAC input," and a CAC is not required for every LCD. The two- to three-year tenure guidance is gone. The elected physician co-chair structure is gone; member approval now rests simply with the MAC. The dissemination-to-societies role is gone, because the statutory public-comment process now performs that solicitation directly and at scale. The reference to the Practicing Physicians Advisory Council is gone (PPAC itself had been sunset earlier in the decade). The substitution rule tightens and formalizes — a substitute may attend only if the MAC is notified and approves at least one week ahead — which is the housekeeping you would expect once a meeting is a recorded, public event of record. About the only provision carried forward verbatim is the honorarium prohibition: participation remains voluntary, expenses on the member or the society.

The net trajectory — and why 2015 is the instructive case

Put the two eras side by side and the arc is coherent. The carrier-era CAC was a representative standing committee — a per-state roster of society delegates, meeting quarterly, functioning as the routing point and comment trigger for draft LCDs, steered by the contractor medical director and an elected physician. The Cures-era CAC is an evidence-review panel — convened at jurisdictional or multi-jurisdictional scale, often stocked with national figures chosen for expertise rather than in-state constituency, addressing a future topic through structured questions in a recorded, public, transcribed session that becomes part of the LCD record, with the comment period and the proposed-LCD posting hived off into their own statutory channels.

The 2015 document is instructive precisely because it isn't a transition. It shows that as late as 2015 CMS was content to leave the 2004 design frozen, which means the 2019 change was not a slow evolution but a single discontinuous response to a statutory mandate. The "many other ad hoc changes" — the multi-jurisdictional option, the substitution mechanics, the recording medium, the closable fraud-and-abuse portions — are best read as CMS using the Cures rewrite as the occasion to clear a decade of deferred modernization in one transmittal.

One caveat for readers who want to follow the functions rather than the committee: these provisions capture the CAC specifically. The full 2019 Chapter 13 rewrite also created or relocated the informal pre-LCD meeting, the formal open meeting, the new-LCD request process, and the comment-and-response (RTC) machinery. Those companion provisions are what make the upstream repositioning of the CAC coherent. The dissemination and comment functions the CAC used to carry did not vanish in 2019; they were redistributed into a statutory public process that the committee no longer needs to host.

Key documents

A few practical notes for the Compose paste: the table should land as an editable Blogger table, and the bracketed links become live hyperlinks automatically. If your template already prints the post title from the title field, just delete the top # From Carrier to Contractor… line after pasting to avoid a doubled headline. And if any single element (most likely the table) comes in looking plain, the table is the one thing that occasionally needs a nudge — let me know and I can hand it to you as a simpler two-column layout that survives Compose more reliably.